Associations - ALK rearrangement

ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2	alectinib Sensitive: A2 - Guideline alectinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ALK inhibitor Sensitive: A2 - Guideline ALK inhibitor Sensitive : A2	ALK inhibitor Sensitive: A2 - Guideline ALK inhibitor Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2	brigatinib Sensitive: A2 - Guideline brigatinib Sensitive : A2
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ceritinib Sensitive: B - Late Trials ceritinib Sensitive : B	ceritinib Sensitive: B - Late Trials ceritinib Sensitive : B
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2
ALK rearrangement	Solid Tumor	ALK rearrangement	Solid Tumor	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2	alectinib Sensitive: C2 – Inclusion Criteria alectinib Sensitive : C2
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	bevacizumab + alectinib Sensitive: C2 – Inclusion Criteria bevacizumab + alectinib Sensitive : C2	bevacizumab + alectinib Sensitive: C2 – Inclusion Criteria bevacizumab + alectinib Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ceritinib + ribociclib Sensitive: C2 – Inclusion Criteria ceritinib + ribociclib Sensitive : C2	ceritinib + ribociclib Sensitive: C2 – Inclusion Criteria ceritinib + ribociclib Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2	camrelizumab + rivoceranib Sensitive: C2 – Inclusion Criteria camrelizumab + rivoceranib Sensitive : C2
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C2 – Inclusion Criteria bevacizumab + atezolizumab Sensitive : C2	bevacizumab + atezolizumab Sensitive: C2 – Inclusion Criteria bevacizumab + atezolizumab Sensitive : C2
ALK rearrangement	Lung Cancer	ALK rearrangement	Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
ALK rearrangement	Lung Cancer	ALK rearrangement	Lung Cancer	crizotinib + lorlatinib Sensitive: C2 – Inclusion Criteria crizotinib + lorlatinib Sensitive : C2	crizotinib + lorlatinib Sensitive: C2 – Inclusion Criteria crizotinib + lorlatinib Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	bevacizumab + crizotinib Sensitive: C3 – Early Trials bevacizumab + crizotinib Sensitive : C3	bevacizumab + crizotinib Sensitive: C3 – Early Trials bevacizumab + crizotinib Sensitive : C3
ALK rearrangement	Lung Adenocarcinoma	ALK rearrangement	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
ALK rearrangement	Non-Hodgkin’s Lymphoma	ALK rearrangement	Non-Hodgkin’s Lymphoma	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	IPI-504 Sensitive: C3 – Early Trials IPI-504 Sensitive : C3	IPI-504 Sensitive: C3 – Early Trials IPI-504 Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
ALK rearrangement	Lung Non-Small Cell Squamous Cancer	ALK rearrangement	Lung Non-Small Cell Squamous Cancer	ALK inhibitor Sensitive: C3 – Early Trials ALK inhibitor Sensitive : C3	ALK inhibitor Sensitive: C3 – Early Trials ALK inhibitor Sensitive : C3
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	iruplinalkib Sensitive: C3 – Early Trials iruplinalkib Sensitive : C3	iruplinalkib Sensitive: C3 – Early Trials iruplinalkib Sensitive : C3
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
ALK rearrangement	Renal Cell Carcinoma	ALK rearrangement	Renal Cell Carcinoma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
ALK rearrangement	Sarcoma	ALK rearrangement	Sarcoma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4